Table I.
Clinical characteristics of JIA patients included in the study
| Patient | Sex | JIA form | Age | Disease duration | No. active jointsa | ESR | Treatment |
|---|---|---|---|---|---|---|---|
| yr | yr | mm/first hour | |||||
| 1 | F | polyarticular RF- | 6.2 | 3.5 | 25 | 20 | MTX, CyA |
| 2 | F | extended oligoarticular | 2.8 | 0.9 | 20 | 36 | NSAID |
| 3 | F | extended oligoarticular | 9.5 | 7.1 | 2 | 96 | MTX |
| 4 | F | polyarticular RF- | 5.4 | 0.8 | 27 | 53 | NSAID |
| 5 | F | extended oligoarticular | 10.4 | 9.3 | 7 | 34 | MTX |
| 6 | M | systemic | 4.3 | 1.7 | 4 | 97 | MTX, CS |
| 7 | F | extended oligoarticular | 5.1 | 3.2 | 3 | 25 | MTX |
| 8 | F | extended oligoarticular | 6.9 | 5.0 | 2 | 24 | MTX |
| 9 | F | polyarticular RF- | 5.2 | 1.9 | 8 | 20 | MTX, NSAID |
| 10 | F | extended oligoarticular | 6.3 | 5.2 | 6 | 60 | MTX |
| 11 | F | polyarticular RF- | 9.9 | 8.5 | 3 | 34 | CyA, NSAID |
| 12 | F | systemic | 10.3 | 0.8 | 16 | 96 | MTX, NSAID |
| 13 | F | persistent oligoarticular | 8.5 | 7.1 | 4 | 12 | - |
| 14 | M | persistent oligoarticular | 4.2 | 2.1 | 1 | 11 | NSAID |
| 15 | F | persistent oligoarticular | 12.9 | 4.7 | 1 | 11 | NSAID |
| 16 | F | persistent oligoarticular | 4.0 | 1.3 | 2 | 13 | NSAID |
| 17 | F | persistent oligoarticular | 2.5 | 1.1 | 1 | 11 | NSAID |
| 18 | F | persistent oligoarticular | 9.3 | 6.2 | 3 | 14 | NSAID |
| 19 | F | persistent oligoarticular | 2.9 | 1.6 | 2 | 25 | - |
| 20 | F | persistent oligoarticular | 11.9 | 3.1 | 1 | 26 | NSAID |
| 21 | F | persistent oligoarticular | 6.0 | 1.6 | 2 | 36 | - |
| 22 | F | persistent oligoarticular | 3.6 | 1.9 | 2 | 14 | NSAID |
| 23 | F | persistent oligoarticular | 6.7 | 5.8 | 1 | 18 | NSAID |
| 24 | F | persistent oligoarticular | 8.1 | 3.6 | 2 | 26 | NSAID |
| 25 | M | persistent oligoarticular | 14.2 | 9.3 | 1 | 12 | NSAID |
a
Defined as presence of swelling and/or limitation of motion with tenderness.
CS, corticosteroids, CyA, cyclosporin A; ESR, erythrocyte sedimentation rate; MTX, methotrexate; NSAID, nonsteroidal antiinflammatory drugs; RF, rheumatoid factor.